Last edition
News about "Lantern Pharma "
Lantern Pharma Launches Innovative AI-Powered Module to Advance ADC Development for Cancer
The global ADC market is projected to reach USD 30.4 billion by 2028, growing at a CAGR of 41.7 percent, with several recently approved ADCs achieving blockbuster status with annual sales exceeding USD 1 billion.
Lantern Pharma | 28/01/2025 | By Aishwarya
The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.
Lantern Pharma | 10/12/2024 | By Aishwarya
Lantern Pharma Gets Regulatory Approval to Expand Harmonic Clinical Trial for NSCLC
Lantern Pharma Inc. has secured regulatory approval to expand its Harmonic trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer (NSCLC) in never-smokers in both Japan and Taiwan.
Lantern Pharma | 23/04/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy